Next Generation News and Research

RSS

WashU Medicine receives $10.8 million grant to advance blood cancer research

Continuing its role as a leader in leukemia research, Washington University School of Medicine in St. Louis has been awarded a five-year, $10.8 million grant to further its exceptional programs in leukemia and other blood cancers.

16 Dec 2024

Collaborative project seeks to close diagnostic gap in asthma care

Asthma affects more than 260M people worldwide and nearly 28M people in the U.S. alone, where, on average, 10 people die from attacks of the chronic disease each day.

16 Dec 2024

Scientists create blood test to enhance cancer treatment effectiveness

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

16 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Fairjourney Biologics establishes Scientific Advisory Board

FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced it has established a Scientific Advisory Board (SAB) to support its strategy for ongoing growth and innovation.

16 Dec 2024

AI revolutionizes cancer research with advanced tools

Significant advancements in understanding the molecular and cellular mechanisms of tumor progression have been made, yet challenges remain.

13 Dec 2024

UMD researcher aims to uncover "ghost networks" in Medicare Advantage health insurance plans

Dr. Mika Hamer is about to go ghost hunting. Thanks to a $100K grant from the Robert Johnson Wood Foundation (RWJF), the University of Maryland School of Public Health researcher aims to uncover the extent of so-called "ghost networks" in Medicare Advantage health insurance plans.

12 Dec 2024

Next-generation cell-penetrating antibodies could transform cancer treatment

A news feature on the research paper "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition" by Rackear et al. was published in Oncotarget's Volume 15 on November 22, 2024, titled "Advancements in cell-penetrating monoclonal antibody treatment."

11 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Study reveals ableism as a barrier to mental health care for disabled individuals

People with disabilities (PWD) make up 25% of the U.S. population. They face elevated mental health concerns and are more likely to utilize mental health services compared to non-disabled individuals.

11 Dec 2024

Mayo Clinic researchers advocate for comprehensive TPMT genotyping across ancestries

Mayo Clinic researchers found that a gene variant, the TPMT∗8 allele, is associated with reduced metabolism of the thiopurine class of drugs. TPMT∗8 is relatively common in individuals of African or African American descent. A novel study in The Journal of Molecular Diagnostics, published by Elsevier, details the researchers' goal to provide pharmacogenomic testing that can be used clinically to predict drug response that is beneficial to all patients, regardless of their ancestral background.

11 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

Scripps Research develops brain-inspired AI for real-time video analysis

Imagine an artificial intelligence (AI) model that can watch and understand moving images with the subtlety of a human brain.

9 Dec 2024

47th annual San Antonio Breast Cancer Symposium kicks off in December

Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), in partnership with the American Association for Cancer Research (AACR), is hosting the 47th annual San Antonio Breast Cancer Symposium at the Henry B. Gonzalez Convention Center on Dec. 10-13.

9 Dec 2024

Breakthrough treatment improves survival rates for children with B-ALL

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children.

9 Dec 2024

New Marie Skłodowska-Curie Doctoral Network advances AI solutions for Parkinson’s disease

Neurological disorders are now the leading cause of disability worldwide. Parkinson's disease is the second most common neurodegenerative disorder, and case numbers are growing quickly.

6 Dec 2024

Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, today announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery.

From Orbit Discovery 3 Dec 2024

Kennesaw State professor receives grant to study cancer treatment access in Kenya

Kennesaw State University professor Herman "Gene" Ray has received a grant from the National Cancer Institute of Kenya to understand the relationship between access to treatment and outcomes in the presence of healthcare reforms enacted in Kenya.

2 Dec 2024

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.

27 Nov 2024

Scientists decode ovarian aging with groundbreaking molecular atlas

Researchers unveil a comprehensive multi-omics atlas of ovarian aging, highlighting coordinated gene expression changes, mTOR signaling, and cellular communication as key to understanding fertility decline.

26 Nov 2024